Clinical Report: Neonatal CD19+B220lo B Cells Respond to Microbiota Through TLR2/4 Activation
Overview
This study investigates the role of neonatal CD19+B220lo B cells in the lungs, highlighting their response to microbiota through TLR2 and TLR4 activation. Findings indicate that this activation promotes B cell proliferation and differentiation.
Background
Neonatal respiratory infections are a significant cause of morbidity and mortality, emphasizing the need to understand immune responses in this vulnerable population. B cell populations, particularly CD19+B220lo cells in the lungs, play a crucial role in the adaptive immune response.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
CD19+B220lo B cells are present in neonatal lungs and respond to microbiota.
Activation via TLR2 and TLR4 ligands induces proliferation and differentiation of these B cells.
In vitro stimulation with TLR ligands leads to the generation of CD138+ cells and the release of IgM, IgG1, and small amounts of IgA.
Lung cultures exhibit an inflammatory cytokine profile, while spleen cultures show a regulatory profile.
Antibiotic treatment reduces the number of CD19+B220lo cells and alters their immunoglobulin repertoire.
Clinical Implications
The findings indicate that neonatal B cells in the lungs can be activated by microbiota.
Conclusion
The study highlights the importance of neonatal CD19+B220lo B cells in responding to microbiota through TLR activation.
by Carolina Ruiz-Sánchez, Isabel Cortegano, Mercedes Rodríguez, Rodrigo Sanchez-Tarjuelo, Alejandro Arrabal, M. Carmen Prado, Mario Alia, M.Pilar Jiménez, Victor Manuel Lopez Molina, Sara Monzón, Victoria López-Alonso, Belén de Andrés, Maria-Luisa Gaspar
